August 1, 2020 | Volume 80 | Number 15

CANCER RESEARCH

TABLE OF CONTENTS

BREAKING INSIGHTS

OBITUARY

REVIEW

CANCER RESEARCH HIGHLIGHTS

MOLECULAR CELL BIOLOGY

TUMOR BIOLOGY AND IMMUNOLOGY

TABLE OF CONTENTS

CONVERGENCE AND TECHNOLOGIES

RESOURCE REPORT

AC AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

In this issue, Principe and colleagues explored gemcitabine-induced alterations to the pancreatic tumor microenvironment (TME) in order to identify potential treatment strategies for patients who progress on cytotoxic chemotherapy. They found that gemcitabine leads to extensive reprogramming of the pancreatic TME, sensitizing mice to a multidrug immunotherapy regimen. In the cover image, they examined the pancreas of a tumor-bearing mouse treated with gemcitabine in the setting of TGFβ and PD-1 signal inhibition. Tissues were stained for the duct marker CK19 (green) and the cytotoxic immune surrogate granzyme B (red). This affirmed the restoration of a functional antitumor immune response and suggests that this approach may warrant consideration in the treatment of gemcitabine-refractory pancreatic ductal adenocarcinoma. For details, see article by Principe and colleagues on page 3101.



Cancer Research
The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

AACR American Association for Cancer Research

80 (15)

Cancer Res 2020;80:3057-3174.